Biochips Market Projected to Reach USD 37.73 Bn by 2032, Growing at 16.0% CAGR
Biochips Market, By Product Type (DNA Chips, Protein Chips, Lab-on-chip Tissue Arrays, Cell Arrays), By End User (Biotechnology and Pharmaceutical Companies, Academic & Research Institutes, Hospitals and Diagnostic Centers, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
According to a recent report by Coherent Market Insights, Global Biochips market is estimated to be valued at USD 13.34 Bn in 2025 and is expected to reach USD 37.73 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 16.0% from 2025 to 2032. Increasing application of biochips in the field of proteomics, genomics and drug discovery can drive the market growth. Extensive R&D activities in the field of healthcare and growing demand for point-of-care testing and diagnostics can also boost demand for biochips during the forecast period.
Global Biochips Market Key Takeaways
According to Coherent Market Insights (CMI), the global biochips market size is projected to grow at a robust CAGR of 16%, from USD 13.34 Bn in 2025 to USD 37.73 Bn by 2032.
Based on product type, DNA chips segment is expected to account for over two-fifths of the global biochips market in 2025.
By end user, biotechnology and pharmaceuticals segment will likely hold a market share of 35.1% by 2025.
North America is anticipated to retain its dominance, holding a market share of nearly 2/5 in 2025.
As per CMIs' new biochips market analysis, Asia Pacific is expected to experience fastest growth during the forecast period.
Growing Demand for Personalized Medicine Boosting Market Growth
Coherent Market Insights' latest biochips market research report highlights major factors driving industry growth. One such prominent growth factor is the increasing demand for personalized medicine.
Biochips are a key enabling technology in personalized medicine. They enable rapid and accurate analysis of an individual's genetic and proteomic profiles. This supports pharmacogenomics, helps in creating tailored treatment plans, and facilitates targeted therapies.
These capabilities are especially valuable in managing complex diseases such as cancer. Thus, growing interest in personalized medicine will continue to provide a strong impetus for the growth of biochips market in the coming years.
High Cost of Biochips and Adoption of Alternative Technologies Limiting Market Growth
The future biochips market outlook looks promising. However, high cost of bioships and associated equipment, along with growing usage of alternative technologies, remain a significant barrier to broader market growth.
Biochips are quite expensive due to their complex manufacturing processes and the need for specialized instrumentation. This high cost limits their accessibility, particularly among small and mid-sized laboratories, thereby reducing overall biochips market demand.
Many end users are turning to alternative technologies like immunoassays, qPCR, and next-generation sequencing (NGS) due to their accuracy and cost-efficiency. This trend may also negatively impact the biochips market growth in the coming years.
Growing Adoption in Disease Diagnostics Creating Lucrative Growth Opportunities
Biochips are being increasingly used in the diagnosis of cancer, genetic disorders, and infectious diseases due to their high accuracy and speed. Their rising adoption in disease diagnostics is expected to create lucrative growth opportunities for biochip manufacturers during the forecast period.
Rising incidence of chronic and infectious diseases, such as COVID-19, is creating a strong need for rapid diagnostics. This is expected to drive demand for biochips, as they offer fast and multiplexed detection of pathogens, making them ideal for point-of-care testing.
Get Up to 25% Discount on the US Tariff Impact Analysis Report: https://www.coherentmarketinsights.com/insight/buy-now/1146
Impact of AI on the Biochips Market
Artificial Intelligence (AI) is making a profound impact on the biochips market. It enhances data analysis, diagnostics, and personalized medicine.
AI algorithms significantly improve the accuracy and speed of disease detection by rapidly interpreting complex biological data produced by biochips. This powerful combination accelerates drug discovery and enables real-time health monitoring.
With ongoing advancements in AI, new applications and efficiencies are expected to emerge. This evolution is poised to propel the biochips market toward greater scalability and precision in delivering advanced healthcare solutions.
Emerging Biochips Market Trends
Growing trend of miniaturization is significantly impacting the biochips market value. Key manufacturers are focusing on developing compact biochips (e.g. lab-on-a-chip systems) with improved features for use in diagnostics, drug discovery, and personalized medicine.
Expanding applications of biochips in drug discovery is expected to foster sales growth. Biochips are increasingly used in drug discovery processes, particularly for gene expression analysis, toxicity profiling, and target identification. These applications are crucial for accelerating pharmaceutical R&D, thereby driving market growth.
There is a growing emphasis on studying genes and proteins to better understand disease mechanisms, identify potential therapeutic targets, and develop personalized medicine approaches. This will likely create a strong demand for biochips in high-throughput research.
Shift toward point-of-care testing (POCT) is expected to create lucrative growth avenues for biochip companies. Portable biochips are being widely used in POCT devices for faster diagnostics at the patient's location.
Ongoing advancements in biochip manufacturing will also support market expansion. Improvements in microfluidics, microarray technology, and semiconductor biochip development are significantly enhancing capabilities of biochips.
Analyst's View
' The global biochips market is expected to record robust growth, owing to increasing incidence of chronic and infectious diseases, rising demand for personalized medicines, and advancements in biochip manufacturing,' said senior analyst Abhijeet Kale.
Current Events and Their Impact on the Biochips Market
Competitor Insights
Key companies listed in biochips market report:
- LinguaFlex
- Inspire Medical Systems, Inc.
- Medtronic
- LivaNova PLC
- SomnoMed
- Nihon Kohden Corporation
- Siesta Medical Inc.
- ResMed
- Koninklijke Philips N.V.
- Somnowell
- Nyxoah SA
- Fisher & Paykel Healthcare Limited
- VYAIRE
- Natus Medical Incorporated
- Nox Medical
- Drive DeVilbiss International
- CLEVELAND MEDICAL DEVICES INC.
- Advanced Brain Monitoring, Inc.
- CONTEC MEDICAL SYSTEMS CO., LTD
Key Developments
In January 2025, Coherent Corp launched its new pinhole array biochips. These biochips are specifically designed for medical diagnostics, with a strong focus on gene sequencing applications.
In May 2025, Archer Materials Limited partnered with Paragraf Limited for Biochip development. This partnership is intended to help Archer advance its Biochip for at-home testing of chronic kidney disease.
Market Segmentation
By Product Type
DNA Chips
Cancer Diagnosis and Treatment
Gene Expression
SNP Genotyping
Genomics
Drug Discovery
Agricultural Biotechnology
Others
Protein Chips
Proteomics
Expression Profiling
Diagnostics
HTS
Others
Lab-on-chip
IVD & POC
Others
Tissue Arrays
Cell Arrays
By End User
Biotechnology and Pharmaceutical Companies
Academic & Research Institutes
Hospitals and Diagnostic Centers
Others
About Us:Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.
Media Contact
Company Name: Coherent Market Insights
Contact Person: Mr. Shah
Email: Send Email
Phone: + 12524771362
Address: 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States Burlingame
City: Burlingame
State: California
Country: United States
Website: https://www.coherentmarketinsights.com/market-insight/biochips-market-1146
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
an hour ago
- National Post
Ottawa in 'serious breach' in allowing used choppers to patrol border, industry says
OTTAWA — Canada's helicopter industry is charging the federal government with a 'serious breach' in allowing the RCMP to patrol the Canada-U.S. border with antiquated military helicopters that don't meet the government's own safety regulations, National Post has learned. Article content The second-hand helicopters, purchased on the open market by private Canadian operators who were then hired by the RCMP, were granted highly unusual special exemptions by Transport Canada. But documents show that the industry is accusing the federal government of breaking its own rules by allowing used choppers that don't meet Canadian safety standards and aren't supposed to carry passengers or even fly over developed areas. Article content Article content Article content 'It's not even something that should be considered,' said Trevor Mitchell, chief executive of the Helicopter Association of Canada (HAC), about the government's decision to provide the special exemptions. 'Why do some have to follow the rules and some don't?' Article content Article content For at least the last three years, the RCMP has been relying on a small number of private contractors to help patrol the border in search of illegal migrants, drug smugglers and other illicit activities. Those contractors, including two based in Ontario, have been using up to four Black Hawk helicopters that were purchased on the second-hand market after the U.S. military decided to update much of its own fleet. Article content According to the government's Canadian Civil Aircraft Register, the second-hand Sikorsky Black Hawk UH 60As are each at least 40 years old and were imported between 2022 and last year. Article content The special exemptions from Transport Canada, the industry says in a series of letters to senior government officials, allowed them to do non-military jobs in Canadian air space. Article content Article content HAC also says that the twin-engine Black Hawks didn't come with 'type certificates,' which act like recipe books for new owners in that they provide details about the aircraft's parts and how it should be maintained. Article content Article content But in a March 20 letter to Transport Minister Chrystia Freeland, Mitchell said even the conditions attached to the exemptions — such as not being allowed to carry passengers or fly over developed areas — have not been followed. 'We urge you to direct your department to ensure the safety restrictions attached to these aircraft are strictly enforced for the balance of the RCMP's contract and that the Force be urged to select a certified aircraft before the contract expires.' Article content The Canadian helicopter industry, which relies heavily on conforming to streams of rules and regulations as its safety pillars, is angry and confused over Transport's decision, Mitchell said. 'It's the hottest topic in the industry.'
Globe and Mail
an hour ago
- Globe and Mail
Here's Why Nvidia Caused BNP Paribas to Downgrade Arista Networks Stock (ANET)
Shares of Arista Networks (ANET) are down at the time of writing after the cloud networking firm was downgraded by BNP Paribas. In fact, 4.5-star analyst Karl Ackerman lowered his rating on the stock from Outperform to Neutral due to increasing competitive pressure from Nvidia (NVDA) and low-cost whitebox vendors like Celestica (CLS) and Accton. These new threats could take market share away from Arista in the AI networking space. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Ackerman explained that the AI networking market is shifting quickly from Ethernet to InfiniBand, with Nvidia and other companies positioned to dominate this segment. Indeed, Nvidia's upcoming Quantum-X switches, which are expected to support 1.6T speeds and launch in the second half of 2025 — about a year ahead of comparable Ethernet products — may significantly limit Arista's near-term growth opportunities. In addition, the move toward rack-scale GPU architectures is accelerating this shift, thereby giving Nvidia and other players an advantage when it comes to capturing the bulk of the Ethernet switching market. As a result of these competitive pressures, Ackerman revised his outlook for Arista's AI-related revenue. He now expects the company to generate $2.5 billion in AI sales by 2027, which is down significantly from his previous forecast of $3.4 billion. Is ANET Stock a Good Buy? Turning to Wall Street, analysts have a Moderate Buy consensus rating on ANET stock based on 11 Buys, four Holds, and zero Sells assigned in the past three months, as indicated by the graphic below. Furthermore, the average ANET price target of $109.38 per share implies 17% upside potential. See more ANET analyst ratings
Globe and Mail
an hour ago
- Globe and Mail
History Says the Nasdaq Will Soar: 1 Brilliant AI Stock to Buy Now, According to Wall Street
Earlier this year, the Nasdaq Composite (NASDAQINDEX: ^IXIC) dropped into market correction territory as investors reacted to the prospect of sweeping tariffs. However, the index has historically rebounded sharply following those incidences, producing an average 12-month return of 21% following corrections since 2010. More broadly, the Nasdaq Composite has returned 11% annually over the last four decades. That suggests the index is headed much higher in the future. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Buying stock in The Trade Desk (NASDAQ: TTD) is a smart way for patient investors to lean into that possibility. Wall Street's median target price of $84 per share implies 23% upside from the current share price of $68. Here are the important details. The investment thesis for The Trade Desk The Trade Desk is an adtech company that operates the largest independent demand-side platform (DSP), software that helps businesses plan, measure, and optimize data-driven advertising campaigns across digital channels. The company has a particularly strong presence in two of the fastest-growing advertising verticals: connected TV (CTV) and retail media. The Trade Desk's independent business model -- meaning it does not own media content and has no reason to steer clients toward specific advertising inventory -- is an important advantage. It distinguishes the company from rivals like Alphabet 's Google, Amazon, and Meta Platforms, all of which have an incentive to sell their own ad inventory to media buyers, whether or not it's the best option. Frost & Sullivan analysts recently recognized The Trade Desk as the most technologically sophisticated DSP on the market. The company has been building artificial intelligence (AI) into its software for years. Its 2023 launch of the Kokai platform introduced new AI features that let agencies manage budgets, prioritize ad impressions, and target consumers. CEO Jeff Green said Kokai adoption was "ahead of schedule" on the first-quarter earnings call, and he thinks all clients will be using the platform by year-end. The Trade Desk is monetizing AI in other ways as well. Its recent partnership with Rembrand will allow brands to use generative AI to create advertising content. That partnership expands its existing generative AI marketplace. Meanwhile, the company recently reorganized its sales teams to build direct relationships with larger brands rather than working solely with advertising agencies. It also restructured its engineering teams to ship smaller updates more frequently. Those changes have already had an impact on its financial performance. In the first quarter, the Trade Desk reported a 25% increase in sales and a 27% increase in non-GAAP (generally accepted accounting principles) earnings. The Trade Desk stock trades at a reasonable price Importantly, The Trade Desk stock fell sharply after the company missed its fourth-quarter revenue guidance. Investors worried that increased competition from Amazon could pose a serious problem for the company, but I think the market overreacted. The Trade Desk has built trust with clients due to its independent business model, something that Amazon lacks. Indeed, Baron Capital analysts believe the competitive landscape remains quite favorable for The Trade Desk, saying in the firm's first-quarter report: "The market has shown a strong preference for independent and objective platforms that are not vertically integrated with media owners. We believe large advertisers will continue to value The Trade Desk's independence, transparency, and neutrality." With that in mind, The Trade Desk is well positioned to grow its business. Adtech spending is forecast to increase at 14.4% annually through 2030, according to Grand View Research. That should translate into slightly stronger earnings growth as the company continues to gain market share, which makes the current valuation of 40 times adjusted earnings look reasonable. Should you invest $1,000 in The Trade Desk right now? Before you buy stock in The Trade Desk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and The Trade Desk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $658,297!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $883,386!* Now, it's worth noting Stock Advisor 's total average return is992% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Trevor Jennewine has positions in Amazon and The Trade Desk. The Motley Fool has positions in and recommends Alphabet, Amazon, Meta Platforms, and The Trade Desk. The Motley Fool has a disclosure policy.
